• 1
    Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007; 20: 440458.
  • 2
    Walsh TR, Toleman MA, Poirel L et al. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18: 306325.
  • 3
    Deshpande LM, Jones RN, Fritsche TR et al. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000–2004). Microb Drug Resist 2006; 12: 223230.
  • 4
    Pournaras S, Ikonomidis A, Tzouvelekis LS et al. VIM-12, a novel plasmid-mediated metallo-beta-lactamase from Klebsiella pneumoniae that resembles a VIM-1/VIM-2 hybrid. Antimicrob Agents Chemother 2005; 49: 51535156.
  • 5
    Giakkoupi P, Xanthaki A, Kanelopoulou M et al. VIM-1 Metallo-beta-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J Clin Microbiol 2003; 41: 38933896.
  • 6
    Aschbacher R, Doumith M, Livermore DM et al. Linkage of acquired quinolone resistance (qnrS1) and metallo-beta-lactamase (blaVIM-1) genes in multiple species of Enterobacteriaceae from Bolzano, Italy. J Antimicrob Chemother 2008; 61: 515523.
  • 7
    Weile J, Ohler S, Schonthal S et al. A VIM-1 metallo-beta-lactamase-producing Klebsiella pneumoniae clinical isolate in an acute hospital in Germany. Int J Antimicrob Agents 2009; 33: 389391.
  • 8
    Tortola MT, Lavilla S, Miro E et al. First detection of a carbapenem-hydrolyzing metalloenzyme in two Enterobacteriaceae isolates in Spain. Antimicrob Agents Chemother 2005; 49: 34923494.
  • 9
    Tato M, Coque TM, Ruiz-Garbajosa P et al. Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-beta-lactamase in Spain: toward endemicity? Clin Infect Dis 2007; 45: 11711178.
  • 10
    Psichogiou M, Tassios PT, Avlamis A et al. Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. J Antimicrob Chemother 2008; 61: 5963.
  • 11
    Kassis-Chikhani N, Decre D, Gautier V et al. First outbreak of multidrug-resistant Klebsiella pneumoniae carrying blaVIM-1 and blaSHV-5 in a French university hospital. J Antimicrob Chemother 2006; 57: 142145.
  • 12
    Ktari S, Arlet G, Mnif B et al. Emergence of multidrug-resistant Klebsiella pneumoniae isolates producing VIM-4 metallo-beta-lactamase, CTX-M-15 extended-spectrum beta-lactamase, and CMY-4 AmpC beta-lactamase in a Tunisian university hospital. Antimicrob Agents Chemother 2006; 50: 41984201.
  • 13
    Galani I, Rekatsina PD, Hatzaki D et al. Evaluation of different laboratory tests for the detection of metallo-beta-lactamase production in Enterobacteriaceae. J Antimicrob Chemother 2008; 61: 548553.
  • 14
    Picao RC, Andrade SS, Nicoletti AG et al. Metallo-beta-lactamase detection: comparative evaluation of double-disk synergy versus combined disk tests for IMP-, GIM-, SIM-, SPM-, or VIM-producing isolates. J Clin Microbiol 2008; 46: 20282037.
  • 15
    Castanheira M, Sader H, Deshpande L et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and Metallo-beta-lactamase-producing Enterobacteriaceae. report from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 2008; 52: 570573.
  • 16
    Conejo MC, Hernandez JR, Pascual A. Effect of porin loss on the activity of tigecycline against Klebsiella pneumoniae producing extended-spectrum beta-lactamases or plasmid-mediated AmpC-type beta-lactamases. Diagn Microbiol Infect Dis 2008; 61: 343345.
  • 17
    Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 19th Informational Supplement. CLSI Document M100-S19. Wayne, PA: CLSI, 2009.
  • 18
    Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002; 8: 321331.
  • 19
    Coque TM, Oliver A, Perez-Diaz JC et al. Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum beta-lactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989 to 2000). Antimicrob Agents Chemother 2002; 46: 500510.
  • 20
    Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed- field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 22332239.
  • 21
    Gulmez D, Woodford N, Palepou MF et al. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. Int J Antimicrob Agents 2008; 31: 523526.
  • 22
    Hong T, Smith Moland E, Abdalhamid B et al. Escherichia coli: developement of carbapenem resistance during therapy. Clin Infect Dis 2005; 40: 8486.
  • 23
    Giakkoupi P, Tzouvelekis LS, Daikos GL et al. Discrepancies and interpretation problems in susceptibility testing of VIM-1-producing Klebsiella pneumoniae isolates. J Clin Microbiol 2005; 43: 494496.
  • 24
    Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 20th Informational Supplement. CLSI Document M100-S20. Wayne, PA: CLSI, 2010.
  • 25
    Cobo J, Morosini MI, Pintado V et al. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta-lactamase-producing Klebsiella pneumoniae epidemic clone. Diagn Microbiol Infect Dis 2008; 60: 319322.
  • 26
    Daly MW, Riddle DJ, Ledeboer NA et al. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy 2007; 27: 10521057.
  • 27
    Anthony KB, Fishman NO, Linkin DR et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46: 567570.
  • 28
    Kelesidis T, Karageorgopoulos DE, Kelesidis I et al. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008; 62: 895904.
  • 29
    Keeney D, Ruzin A, Bradford PA. RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae. Microb Drug Resist 2007; 13: 16.
  • 30
    Rasheed JK, Jay C, Metchock B et al. Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob Agents Chemother 1997; 41: 647653.
  • 31
    Fishman JA. Infection in renal transplant recipients. Semin Nephrol 2007; 27: 445461.